Evidence map›Paper›PMID 26260289›Full record

ArticleMolecular cancer2015

A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.

Chantel Samardzija, Rodney B Luwor, Mila Volchek, Michael A Quinn, Jock K Findlay, Nuzhat Ahmed

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Role of OCT4 in cancer stem-like cells and chemotherapy resistance.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chantel SamardzijaWomen's Cancer Research Centre, Royal Women's Hospital, Victoria, 3052, Australia.
Rodney B LuworDepartment of Surgery, University of Melbourne, Royal Melbourne Hospital, Victoria, 3052, Australia.
Mila VolchekDepartment of Anatomical Pathology, Royal Women's Hospital, Victoria, 3052, Australia.
Michael A QuinnWomen's Cancer Research Centre, Royal Women's Hospital, Victoria, 3052, Australia.
Jock K FindlayWomen's Cancer Research Centre, Royal Women's Hospital, Victoria, 3052, Australia.
Nuzhat AhmedWomen's Cancer Research Centre, Royal Women's Hospital, Victoria, 3052, Australia. nuzhata@unimelb.edu.au.
Royal Women's Hospital · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh grade epithelial ovarian cancer (EOC) is commonly characterised by widespread peritoneal dissemination and ascites. Metastatic EOC tumour cells can attach directly to neighbouring organs or alternatively, maintain long term tumourigenicity and chemoresistance by forming cellular aggregates (spheroids). Cancer stem-like cells are proposed to facilitate this mechanism. This study aimed to investigate the role of Oct4A, an embryonic stem cell factor and known master regulator of pluripotency in EOC progression, metastasis and chemoresistance.

methodsTo investigate the expression of Oct4A in primary EOC tumours, IHC and qRT-PCR analyses were used. The expression of Oct4A in chemonaive and recurrent EOC patient ascites-derived tumour cells samples was investigated by qRT-PCR. The functional role of Oct4A in EOC was evaluated by generating stable knockdown Oct4A clones in the established EOC cell line HEY using shRNA-mediated silencing technology. Cellular proliferation, spheroid forming ability, migration and chemosensitivty following loss of Oct4A in HEY cells was measured by in vitro functional assays. These observations were further validated in an in vivo mouse model using intraperitoneal (IP) injection of established Oct4A KD clones into Balb/c nu/nu mice.

resultsWe demonstrate that, compared to normal ovaries Oct4A expression significantly increases with tumour dedifferentiation. Oct4A expression was also significantly high in the ascites-derived tumour cells of recurrent EOC patients compared to chemonaive patients. Silencing of Oct4A in HEY cells resulted in decreased cellular proliferation, migration, spheroid formation and increased chemosensitivity to cisplatin in vitro. IP injection of Oct4A knockdown cells in vivo produced significantly reduced tumour burden, tumour size and invasiveness in mice, which overall resulted in significantly increased mouse survival rates compared to mice injected with control cells.

conclusionsThis data highlights a crucial role for Oct4A in the progression and metastasis of EOC. Targeting Oct4A may prove to be an effective strategy in the treatment and management of epithelial ovarian tumours.

Indexed as

AnimalsAntigens, NeoplasmBiomarkersCell Adhesion MoleculesCell Line, TumorCell MovementCell ProliferationCisplatinCystadenocarcinoma, SerousDisease Models, AnimalDrug Resistance, NeoplasmEpithelial Cell Adhesion MoleculeFemaleGene ExpressionGene Knockdown TechniquesHeterograftsAntigens, NeoplasmBiomarkersCell Adhesion MoleculesCisplatinEpithelial Cell Adhesion MoleculeHyaluronan ReceptorsLin28A protein, humanOctamer Transcription Factor-3RNA-Binding ProteinsRNA, Small InterferingSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID26260289
PMCPMC4531496
OpenAlexW2114919734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.